FDA approves Myovant’s relugolix as first once-a-day pill for advanced prostate cancer
18/12/20 Max Gelman
Myvant Sciences, the swiss biotech, won FDA approval for relugolix on Friday, reported Endpoints. It’s the first oral hormone therapy approved for the indication, and will be marketed as Orgovyx. The standard of care, AbbVie’s Lupron, needs to be injected once every three months, with other treatments typically being under-skin implants, while Orgovyx will be a one-a-day pill. Myovant is also expected to approach European regulators for approval for the drug in the first half of next year.